Yifan Tu, MD
Hematology & Oncology · St. Louis, MONPI 1447405899
Payments from drug & device makers
Across 808 payments — averaging $527.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$174K
- Regeneron$149K
- GSK$28K
- Daiichi Sankyo Inc.$23K
- Pfizer$18K
- Novartis$8K
- plus $26K from 54 others
Across 8 payments — averaging $217.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$2K
What the payments were for
- Consulting fees$32,66751%
- Speaking & faculty fees$9,29015%
- Travel & lodging$2,0393%
- Food & beverage$19,50331%
- Education$470%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$426,138 in reported general payments places this provider in the 90th percentile of 211 hematology & oncology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 38 | $536,551 |
| JakafiRuxolitinib Phosphate | 31 | $530,460 |
| IbrancePalbociclib | 33 | $520,895 |
| VerzenioAbemaciclib | 35 | $510,681 |
| ErleadaApalutamide | 34 | $492,364 |
| DopteletAvatrombopag Maleate | 49 | $464,997 |
| AyvakitAvapritinib | 12 | $448,254 |
| CalquenceAcalabrutinib Maleate | 22 | $380,265 |
| KisqaliRibociclib Succinate | 19 | $322,762 |
| LenvimaLenvatinib Mesylate | 13 | $311,587 |
| TasignaNilotinib Hcl | 12 | $236,647 |
| ZejulaNiraparib Tosylate | 12 | $224,314 |
| XtandiEnzalutamide | 15 | $215,913 |
| ImbruvicaIbrutinib | 13 | $204,013 |
| PromactaEltrombopag Olamine | 14 | $152,374 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisKisqali, Tasigna, Promacta | $7,683 | $711,78245 claims |
| PfizerIbrance, Bosulif, Eliquis | $18,386 | $618,284108 claims |
| Bristol Myers SquibbRevlimid | $502 | $536,55138 claims |
| Incyte CorporationJakafi | $396 | $530,46031 claims |
| Johnson & JohnsonErleada, Xarelto | $1,040 | $526,17269 claims |
| Lilly USA, LLCVerzenio | $250 | $510,68135 claims |
| Blueprint Medicines CorporationAyvakit | $155 | $448,25412 claims |
| AstraZenecaCalquence | $174,288 | $380,26522 claims |
| Eisai Inc.Lenvima | $637 | $311,58713 claims |
| GSKZejula | $28,459 | $224,31412 claims |
| Astellas Pharma US IncXtandi | $235 | $215,91315 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $220 | $204,01313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 211 hematology & oncology providers in Missouri.
Other hematology & oncology in St. Louis
- Sagun GoyalSt. Louis$131K
- Stephanie GraffKansas City$6.2M
- Suman KambhampatiKansas City$4.9M
- Geoffrey UySaint Louis$4.1M
- Jaswinder SinghKansas City$3.9M
- Mark FeslerSaint Louis$2M
- James MosleyCape Girardeau$1.7M
- Shahzad RazaKansas City$1.7M
- Gerhard HildebrandtColumbia$1.6M
- David SchlossmanColumbia$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.